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To the Editors,
We read the article by Dretler et al.1 regarding meningococcal
disease and vaccination with great interest. As stated in this
review, individuals receiving the complement inhibitor eculizu-
mab are at increased risk for invasive meningococcal disease.
Eculizumab (Soliris, Alexion Pharmaceuticals), is a humanized
monoclonal antibody that is a terminal complement inhibitor
used to treat atypical hemolytic uremic syndrome (aHUS).2
Administration of eculizumab has been associated with a 1000-
fold to 2000-fold increased incidence of meningococcal
disease.3 Current Advisory Committee on Immunization Practi-
ces guidelines recommend that eculizumab recipients should be
vaccinated with both quadrivalent meningococcal conjugate
(MenACWY) and serogroup B (MenB) meningococcal
vaccines.1 Clinicians could also consider antimicrobial prophy-
laxis for the duration of eculizumab treatment to reduce the risk
for meningococcal disease. However, neither vaccination nor
antibiotic prophylaxis provides complete protection in patients
receiving eculizumab treatment.3 Thus, as stated by Dretler et
al.,1D1 the ideal management for these patients remains challeng-
ing. Here, we present an 11-year-old boy with aHUS treated
with eculizumab who developed fatal meningococcemia due to
Neisseria meningitidis serogroup Y 16 months after receiving
two doses of MenACWY-D (first dose: prior to start of eculizu-
mab treatment; second dose: 2 months later) while on oral peni-
cillin prophylaxis. The patient presented to the pediatric
emergency department with fever, chills, headache, and myalgia,
but no rash, or neck stiffness. Treatment with empirical intrave-
nous ceftriaxone was started after blood and cerebrospinal fluid
(CSF) cultures were obtained. Laboratory evaluation revealed
leukopenia (2600/mL [N:4–10.8 £ 103/mL]), thrombocytope-
nia (128000/mL [N:130-400 £ 103/mL]), elevated C reactive
protein (19 mg/dL [N: 0-0,5]), and disseminated intravascular
coagulation (DIC). Lumbar puncture revealed no evidence of
meningitis. Due to rapid deterioration with progressive shock
and multiorgan failure the patient was transferred to pediatric
intensive care unit (PICU). He developed a petechial and pur-
puric rash over his entire body in the first hour after PICU
admission. Despite aggressive fluid resuscitation, inotropic
and ventilatory support, hypotension and respiratory failure
persisted, and the patient died within hours of PICU admis-
sion. Twenty-four hours later, N. meningitidis growth was
noted in blood culture, but not in CSF culture. The bacterial
isolate was sent to the national reference laboratory for sero-
grouping and confirmed as serogroup Y. The N. meningitidis
strain showed intermediate penicilin susceptibility, with a
minimal inhibitory concentration of 0.19 mg/L (sensitive
0.06 mg/L, resistant 0.25 mg/L).
Our case highlights the difficulties in protecting patients on
eculizumab treatment against meningococcal disease, even with
vaccination and antibiotic prophylaxis. Futher studies are
needed to investigate the potential efficacy and duration of
protection of meningococcal conjugate vaccines in pediatric
eculizumab recipients.
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